Pharmacoepidemiology of chronic noncancer pain patients requiring chronic opioid therapy: A nationwide population-based study

Pharmacoepidemiology of chronic noncancer pain patients requiring chronic opioid therapy: A nationwide population-based study

Acta Anaesthesiologica Taiwanica xxx (2015) 1e6 Contents lists available at ScienceDirect Acta Anaesthesiologica Taiwanica journal homepage: www.e-a...

250KB Sizes 3 Downloads 57 Views

Acta Anaesthesiologica Taiwanica xxx (2015) 1e6

Contents lists available at ScienceDirect

Acta Anaesthesiologica Taiwanica journal homepage: www.e-aat.com

Original Article

Pharmacoepidemiology of chronic noncancer pain patients requiring chronic opioid therapy: A nationwide population-based study Shu-Ching Chang 1, Chen-Chung Ma 2, Chun-Te Lee 3, Shao-Wei Hsieh 1 * 1

Division of Anesthesiology, E-DA Hospital, Kaohsiung, Taiwan Department of Healthcare Administration, I-Shou University, Kaohsiung, Taiwan 3 Department of Leisure and Sports Management, Cheng-Shiu University, Kaohsiung, Taiwan 2

a r t i c l e i n f o

a b s t r a c t

Article history: Received 17 March 2014 Received in revised form 30 March 2015 Accepted 11 April 2015

Objective: This study was aimed to explore the pharmacoepidemiology of chronic noncancer pain (CNCP) patients who required chronic opioid therapy (COT) in the Taiwanese population. Methods: Using the Taiwan National Health Insurance Research Database during 2008e2009, COTrequiring CNCP patients were identified by the inclusion criteria of both chronic analgesic requirement for > 3 months per year and long-term use of controlled opioids for > 28 therapeutic days during any 3-month period in ambulatory visits with malignancy-related pain excluded. Their demographic data and pharmacoepidemiological characteristics of opioid consumption and opioid prescriptions issued in ambulatory visits were analyzed. Results: In total, 159 patients were enrolled as COT-requiring CNCP patients, and the prevalence was calculated at 0.016% in a 2-year period. Females were outnumbered by males (45.3% vs. 54.7%). Almost 60% of them were of working age and 93.7% belonged to low-income households, as in the health insurance claims, probably implying socioeconomic disadvantages associated with CNCP. The leading three diagnoses were unspecified myalgia and myositis, lumbago, and abdominal pain of unspecified site. The most common department from where these 159 CNCP patients obtained their opioid prescriptions was the emergency department (27.6%), ensued by a pain clinic (25.3%), but they could acquire only a few opioid therapeutic days through emergency department visits. Moreover, pain clinic satisfied the majority of opioid therapeutic days. Among all opioids, morphine was the most frequently prescribed in opioid-obtaining ambulatory visits, accounting for most of the opioid therapeutic days as well as opioid consumption. Conclusion: COT-requiring CNCP patients were easily associated with adverse socioeconomic liabilities and often visited emergency department as well as pain clinics. Morphine was the main opioid used for their chronic pain. Transfer of COT-requiring CNCP patients to appropriate departments is strongly recommended for efficient long-term pharmacotherapy for their chronic pain. Copyright © 2015, Taiwan Society of Anesthesiologists. Published by Elsevier Taiwan LLC. All rights reserved.

Key words: chronic noncancer pain; chronic opioid therapy; opioid therapeutic days

1. Introduction Chronic noncancer pain (CNCP) is a widespread health problem with pervasive negative effects on physical function and quality of life of the affected individuals.1 In general, all chronic pain conditions other than pain at the end of life or malignancy-related pain are collectively labeled as CNCP.2 CNCP patients have a higher Conflict of interest: None of authors has any financial or nonfinancial competing interest that the authors are aware of in relation to this study. * Corresponding author. Division of Anesthesiology, E-Da Hospital, Number 1, Yida Road, Jiaoshu Village, Yanchao District, Kaohsiung 82445, Taiwan. E-mail address: [email protected] (S.-W. Hsieh).

incidence of pre-existing psychological disorders, and the considerable impact of psychological distress on the pain extent of CNCP have also been well highlighted.1,3 The treatment for CNCP remains a challenge to the primary care physicians, and some of chronic pain patients were poorly satisfied with the treatment they received in primary care clinics.4 Pharmacological treatment is still the mainstay for the treatment of CNCP, and nonpharmacologic strategies, such as nerve blocks and interventional treatments, are also helpful in alleviating chronic pain for some CNCP patients.5,6 As the intractable CNCP cases stand, physicians could consider obligatorily chronic use of opioids for selective patients whose severe CNCP failed to be relieved by

http://dx.doi.org/10.1016/j.aat.2015.04.002 1875-4597/Copyright © 2015, Taiwan Society of Anesthesiologists. Published by Elsevier Taiwan LLC. All rights reserved.

Please cite this article in press as: Chang S-C, et al., Pharmacoepidemiology of chronic noncancer pain patients requiring chronic opioid therapy: A nationwide population-based study, Acta Anaesthesiologica Taiwanica (2015), http://dx.doi.org/10.1016/j.aat.2015.04.002

2

S.-C. Chang et al.

nonsteroidal anti-inflammatory drugs, cyclooxygenase-II inhibitors, or weak opioid agonists other than controlled opioid drugs.7e9 However, the safety, effectiveness and abuse potential of chronic opioid therapy (COT) in patients with chronic noncancer pain still open to debate and under controversies, given the rising prevalence of opioid abuse.10 The prevalence of CNCP varied widely in different countries. The 1-month prevalence of moderate-to-severe CNCP, estimated using systematic review principles, was 19% in pan-Europe.11 Using a literature review, this prevalence was estimated to be 16% in Denmark and 18% in Sweden.12 The prevalence of CNCP, defined as continuous or intermittent pain for at least 6 months, was reported to be 29% among Canadian adults, as surveyed by telephone in 2001.13 In an article, the prevalence of mild chronic pain among the Taiwanese people living in Taipei City was estimated to be 40%, based on the interview of only 219 elderly people with a structured questionnaire.14 Considerable heterogeneity existed in the prevalence in different countries due to a great variety in the population chosen, research methods, pain severity, and chronicity definitions of CNCP in different studies. Nevertheless, the prevalence of CNCP seemingly continues to increase.15,16 A particular subgroup of CNCP patients who required COT regularly requests for more endeavors and medical expertise to get their pain abated, and usually demands more medical services, and often are troubled with more comorbidities.2,17 The 1-year prevalence of COT-requiring CNCP was estimated to be 0.65% in a United States state population survey using insurance claims database, and 3% in Denmark from an interview and questionnaire survey.18,19 However, the prevalence of CNCP in Taiwan was rarely investigated, especially among the severe CNCP patients who demanded COT regularly. Lin et al2 reported that the number of COT-requiring CNCP patients, who were officially superintended and registered on record in the database of the National Bureau of Controlled Drugs (NBCD), Taiwan, in August 2001, was only 114.2 However, it only stood for a confined subgroup of COT-requiring CNCP patients who had severe pain, consumed opioids for a longer time, and were overseen strictly under governmental NBCD surveillance, hardly portraying the actual conditions of CNCP patients treated with opioids habitually in the Taiwanese population. Since clear understanding of CNCP circumstances is important to manage these patients and improve the quality of pain control, we aimed to explore pharmacoepidemiology of CNCP patients who required COT in the Taiwanese population. 2. Materials and methods 2.1. Materials In this retrospective cohort study, we aimed to investigate the epidemiology and medical care utilization of COT-requiring CNCP patients in Taiwan, based on the analyses of secondary data of both 2008 and 2009 from the National Health Insurance Research Database. Created by Taiwan National Health Research Institutes, National Health Insurance Research Database was a representative database of a population of 1 million, which was derived systematically from the entire insurance claim database for reimbursement for beneficiaries of the Taiwan National Health Insurance program. Taiwan launched a single-payer health insurance program in 1996, which provided medical care to over 96% of Taiwanese population enrolled in the program. Since then, a tremendous amount of computerized data, including enrollment data, hospitalization data, drug exposure data, disease diagnosis data, and original claim data for reimbursement, has been accumulated. This database is available to the researchers in Taiwan and suitable for cohort studies on a population-based basis.

2.2. Methods First, noncancer patients, who had no malignancy diagnosis during follow-up in 2008 and 2009, were recruited by means of elimination with the Classification of international code of Diseasesd9th edition (ICP-9) of malignant neoplasms (ICD-9 codes: 140-209 and 230-239) in both inpatient and outpatient claim records from a National Health Insurance Research Database representative database of 1 million population.20 Second, among all noncancer patients, those who both have persistently taken analgesic agents, exclusive of oral or parental nonsteroidal anti-inflammatory drugs and other nonopioid drugs, for over 3 months in 1 year and have managed with controlled opioids confined to outpatient visits for > 28 therapeutic days during any period of 3 months would be enrolled as targeted COTrequiring CNCP patients. Drug prescriptions during hospitalization or at discharge would not be included. This CNCP criterion was comparable with the regulatory ordinance in “Precautions of Longterm Narcotic Prescription for Physicians to Patients with Intractable Chronic Non-cancer Pain” announced in 2004 by the Taiwan Food and Drug Administration (TFDA), Department of Health, Executive Yuan. The controlled opioids commonly used in ambulatory clinics for pain control and regulated by TFDA in 2008 and 2009 included morphine injection (drug codes: A005886209, A005891209, B021452299, A005862209, and B021452243), regular morphine tablet (drug code: A005860100), slow-release morphine tablet (drug codes: B019000100, A042534100, B019001100, and B023779100), meperidine injection (drug code: A005874209), meperidine tablet (drug code: A005858100), transdermal fentanyl patch (drug codes: A050018311, A0517173CS, B021523314, B021525321, B022898314, B022899321, B0248423CS, B0248703B9, and B024889311), codeine injection (drug code: A005889209), codeine tablet (drug codes: A005857100 and A005865100), and sublingual buprenorphine tablet (drug code: B021625100). All these were targeted in this study. Outpatient prescriptions of these five drugs were strictly controlled and overseen under TFDA surveillance. The medical claim records of codeine prescription were excluded if prescribed for diseases of the respiratory system diagnosed (ICD-9 codes: 460-519). The 2-year CNCP prevalence was computed because our own insurance claim databank of 2 years hardly showed a long-term annual trend through the years and the 1-year prevalence of COTrequiring CNCP in the Taiwanese population was very low. Demographic attributes of COT-requiring CNCP patients, including gender, age, district of group insurance units, community urbanization, and household income, were analyzed. The degree of community urbanization of the local district where the patients lived was determined using standards proposed in a previous survey of Taiwan township development.21 The household economic status of CNCP enrollees was determined from their policy identities while joining into Taiwan National Health Insurance program. The demographic low-income household was Category 5 in the insured object classification of the National Health Insurance claim, which was qualified equally to the low-income household members stipulated in Social Assistance Act of Taiwan. The insured of category 5 means someone whose average household member income, divided by all family members, is below the essential minimum of subsistence allowance per person per month. In Taiwan, the minimum income was NTD 9210 in 2008, with limited chattel per person and limited real estate per household. Furthermore, opioid pharmacotherapies in these COT-requiring CNCP patients were also investigated, including all outpatient visits for their pain issue, opioid consumption, and clinical pain disorders, which indicated their opioid medication. To understand utilization of medical services in these patients, we calculated the frequencies

Please cite this article in press as: Chang S-C, et al., Pharmacoepidemiology of chronic noncancer pain patients requiring chronic opioid therapy: A nationwide population-based study, Acta Anaesthesiologica Taiwanica (2015), http://dx.doi.org/10.1016/j.aat.2015.04.002

Pharmacoepidemiology of chronic noncancer pain patients

of outpatient visits in different departments from their outpatient reimbursement claims, including analgesic- and opioid-obtaining outpatient visits. The outpatient visits in which several nonopioid analgesics and opioids were prescribed would be counted once only. To view opioid consumption of CNCP patients, the authors used both opioid therapeutic day (OTD) and oral morphine equivalent dose (OMEQ), instead of medical expenditure, for compatibility with the inclusion criterion of therapeutic day of COT-requiring CNCP in the TFDA regulations. OTD in our study was defined as the duration of days that physicians intended to stifle chronic pain while prescribing opioids to CNCP patients in a single outpatient visit. OMEQ means equivalent dosages of strong opioids (administered through oral, parenteral, or transdermal routes) relative to analgesic strength of oral morphine.22,23 OMEQ conversion factors used were as follows: 1.0 for morphine oral intake, 3 for morphine intravenous or intramuscular injection, 0.25 for codeine intramuscular injection, 0.15 for codeine oral intake, 3.0 for fentanyl transdermal route (from mcg/hr to mg/day), 0.4 for meperidine intravenous or intramuscular injection, 0.1 for meperidine oral intake, and 40 for buprenorphine sublingual use.22 Average OMEQ per ambulatory visit was presented as medians with the 25th and 75th quartiles (Q1 and Q3). Average OTD per opioid-obtaining ambulatory visit, OMEQ, and OTD per opioid prescription were presented as mean ± standard deviation. It is common that more than one diagnostic code, up to a maximum of three, is given for a single outpatient visit. Diagnosed pain disorders of these patients were classified according to chapter codes in ICD-9, including infectious and parasitic diseases (ICD-9 codes: 001e139); neoplasms (ICD-9 codes: 140e239); endocrine, nutritional and metabolic diseases, and immunity disorders (ICD-9 codes: 240e279); disorders of blood (ICD-9 codes: 280e289); mental disorders (ICD-9 codes: 290e319); diseases of the nervous system and sense organs (ICD-9 codes: 320e389); diseases of circulatory system (ICD-9 codes: 390e459); diseases of the respiratory system (ICD-9 codes: 460e519); diseases of the digestive system (ICD-9 codes: 520e579); diseases of the genitourinary system (ICD-9 codes: 580e629); complications of pregnancy, childbirth and the puerperium (ICD-9 codes: 630e677); diseases of the skin and subcutaneous system (ICD-9 codes: 680e709); diseases of the musculoskeletal system and connective tissue (ICD-9 codes: 710e739); symptoms, signs, and ill-defined conditions (ICD9 codes: 780e799); and injury and poisoning (ICD-9 codes: 800e999). Throughout this study, we followed the guidelines and rules for investigation with human individuals set by the institutional review board of E-DA Hospital (IRB number: EMRP-101-055). 3. Results Data of only 159 CNCP patients, who had been suffering from CNCP and required long-term opioid therapy in 2008 and 2009, were collected from the National Health Insurance Database of 1 million population, and the 2-year prevalence was calculated to be 0.016%. Among 159 COT-requiring CNCP patients, the number of males was more than that of females; 59.7% of them were of working age (25e65 years), and patients aged over 65 years accounted for over 40%. Most of these patients lived in urbanized communities (59.1%), especially in Taipei Capital district. Particularly worthy of note, 93.7% of these patients belonged to lowincome households, as per the health insurance policy (Table 1). Nearly half of CNCP patents (46.5%) had visited the emergency department (ED), and over one-fifth (20.8%) had visited pain clinics to obtain opioids for pain control. These CNCP patients seemingly obtained opioid prescriptions more easily in outpatient visits than

3 Table 1 Demographic characteristics of COT-requiring CNCP patients. Variables Gender Male Female Age (y) 25e44 45e64 > 65 Mean 59.2, SD 17.9 Districts of group insurance units Taipei capital district North district Middle district South district Kao-Ping district East district Urbanization Rural area Urban area Households Low-income households Other households

CNCP patients (n ¼ 159) 87 (54.7) 72 (45.3) 42 (26.4) 53 (33.3) 64 (40.3)

44 19 21 38 33 4

(27.7) (11.9) (13.2) (23.9) (20.8) (2.5)

65 (40.9) 94 (59.1) 149 (93.7) 10 (6.3)

Data are presented as n (%). CNCP ¼ chronic noncancer pain; COT ¼ chronic opioid therapy.

pain clinic visits (86.5%, 527 opioid-obtaining visits vs. 609 analgesic-asking visits). Moreover, pain clinics accounted for 44.9% of the total OTD and 74.2% of the total OMEQ of all COT-requiring CNCP patients. Although pain clinics and emergency medicine departments accounted for over half of opioid-obtaining outpatient visits (53.0%), CNCP patients could get only a few OTDs (1.1 ± 0.4 days) in a single visit to the ED (Table 2). More than half of CNCP patents took codeine (57.9%) or morphine (50.9%) for their CNCP. Morphine, codeine, and fentanyl, listed in a decreasing order accounted for most of OTDs of five opioid drugs (88.0%). Surprisingly, in outpatient visits, injection prescriptions of morphine, codeine, and meperidine were prescribed to 36.5%, 11.9%, and 35.2% of 159 CNCP patients, respectively, even on a chronic basis. Among all opioids and drug formulas, morphine SR and regular tablets per oral accounted for the majority of OMEQ (74.1%, summed up) and 43.5% of OTD. The most frequently prescribed opioid was morphine, followed by meperidine, in opioid-obtaining outpatient visits (Table 3). The leading causes of 159 COT-requiring CNCP patients asking for opioids were unspecified myalgia and myositis (ICD-9 729.1), followed by lumbago (ICD-9 724.2) and abdominal pain of unspecified site (ICD-9 789.00). Unspecified neuralgia; neuritis and radiculitis (ICD-9 729.2), synonymous with neuropathic pain; and headache (ICD-9 784.0) were the next commonest causes among these patients (Table 4). 4. Discussion Our study disclosed that only 159 COT-requiring CNCP patients were enrolled in a representative 1 million Taiwanese population during the 2-year period of 2008 and 2009, and its 2-year prevalence was estimated to be 0.016%, far less than in the United States (1-year prevalence 0.65%) or in Denmark (1-year prevalence 3%).18,19 The differences in the COT-requiring CNCP prevalence among various populations resulted partly from the distinct definitions of chronic opioid use, for example, long-term opioid use (OTDs) for over 4 weeks in any 3-month period in Taiwan and chronic opioid use for at least 6 months in the United States, and regular or continuous opioid use in Denmark.18,19 The coding of ICD9 conditions in the Taiwan medical system might not be

Please cite this article in press as: Chang S-C, et al., Pharmacoepidemiology of chronic noncancer pain patients requiring chronic opioid therapy: A nationwide population-based study, Acta Anaesthesiologica Taiwanica (2015), http://dx.doi.org/10.1016/j.aat.2015.04.002

4

S.-C. Chang et al.

Table 2 Utilization distribution of the departments from which 159 COT-requiring CNCP patients obtained their opioid prescriptions within 2 years. Departments

CNCP patientsa (n ¼ 159)

Analgesic-obtaining outpatient visitsb

Opioid-obtaining outpatient visits

OMEQ of all opioids

OMEQ per visit, median (Q1, Q3)

OTD of all opioids

OTD per visit

Emergency medicine Pain therapy Neurosurgery Internal medicine Orthopedics Gastroenterology Other departmentsc Total

74 33 26 26 16 15 78

1015 (17.5) 609 (10.5) 319 (5.5) 577 (9.9) 551 (9.5) 186 (3.2) 2553 (43.9) 5810

583 (27.8) 527 (25.2) 162 (7.7) 101 (4.8) 129 (6.2) 123 (5.9) 466 (22.3) 2091

21,897 (2.1) 775,088 (74.2) 54,347 (5.2) 9550 (0.9) 42,410 (4.1) 69,310 (6.6) 72,525 (6.9) 1,045,125

30 795 252 22.5 126 56 31.5

637 (3.9) 7289 (44.9) 2061 (12.7) 733 (4.5) 1123 (6.6) 875 (5.4) 3535 (21.7) 17,132

1.1 13.8 12.7 7.0 8.7 7.1 7.5

(46.5) (20.8) (16.4) (16.4) (10.1) (9.4) (49.1)

(20, 30) (350, 1860) (101, 378) (20, 90) (20, 750) (20, 1680) (20, 126)

± ± ± ± ± ± ±

0.4 8.0 8.8 10.0 7.7 6.9 8.4

Data are presented as n (%). CNCP ¼ chronic noncancer pain; COT ¼ chronic opioid therapy; NSAID ¼ nonsteroidal anti-inflammatory drug; OMEQ ¼ oral morphine equivalent dose; OTD ¼ opioid therapeutic day. a Some patients obtained their opioid prescription from different departments during the period of 2 years. b All outpatient visits were calculated considering that COT-requiring CNCP patients could get some analgesics in ambulatory visits, including NSAIDs, cyclooxygenase II inhibitors, weak opioids, or controlled strong opioids. c Other departments included cardiovascular surgery, surgery, neurology, nephrology, family physician, genitourinary, hemodialysis, rheumatology, chest medicine, dermatology, plastic surgery, rehabilitation, endocrinology, cardiology, otorhinolaryngology, psychology, general surgery, colorectal surgery, gynecology, infection, and tuberculosis clinics, in the decreasing order of patient numbers. CNCP patients obtained opioids from all departments, and dermatology and the following clinics individually have provided few opioids to less than four patients within 2 years.

adequately accurate; hence, the use of ICD9 codes might introduce selection bias into the study. However, malignancies are of great clinical significance to clinicians, and it is hard to skip malignancy diagnosis completely in all claim records of ambulatory visits and inpatient admissions within the period of 2 years if cancer pain exists; thus, it is appropriate to use ICD9 codes as exclusion criteria to define the noncancer group from all patients. The definition of COT in our study conformed to the official regulations of TFDA, and COT-requiring CNCP patients should be registered in Taiwan with the NBCD, TFDA. Known allegedly, COT-requiring CNCP patients registered in the NBCD list in the whole Taiwan population of 23 million in 2008 and 2009 were counted at several hundred. (The authors failed to get the exact number of registered CNCP patients in NBCD.) The possible causes of the great variation in the COT-requiring CNCP prevalence between the previously published Lin et al's2 report in 2001, NBCD registry, and ours in the same Taiwanese population were the failure of submission to NBCD surveillance in some cases, obtaining opioids from different departments and different physicians, disparity of study years with annual trend of CNCP prevalence, and obviously diverse study methods. Furthermore, several barriers to long-term opioid therapy might also result in a low prevalence of

COT-requiring CNCP in the Taiwanese population, including popular negative beliefs about opioid use, nonacceptance by the local society, and strict legal regulation from the government in Taiwan.24,25 Thus, the real prevalence of severe CNCP might probably be underestimated in Taiwan because of some barriers to COT. Most of epidemiological CNCP surveys agreed that females are more likely to experience CNCP than males, and the overall prevalence of CNCP increases with age.12,26,27 Nevertheless, male COTrequiring CNCP patients outnumbered female patients in our research, and the underlying reason remains unclear. In our research, 60% of these 159 patients (average age 59.2 years) were of working age (25e65 years). Meanwhile, a low-income household prevalence of a remarkably-high 93.7% was disclosed in this group, suggesting that severe CNCP usually have a significant adverse impact on the economic advantages of the victims.17,27,28 Although low-income households, determined by the health insurance claim, did not necessarily reflect the patient's real occupational incapacity, this identity implied that CNCP brought about economic burdens, probably making it difficult for patient families to maintain their basic standard of living. Accordingly, severe CNCP that necessitates COT regularly could cause significant impairment in occupational

Table 3 Consumption of opioids that were prescribed to COT-requiring CNCP patients in outpatient visits within 2 years. Drugs

CNCP patientsa (n ¼ 159)

Opioid prescriptions

Total OMEQ (mg)

Morphine subtotal Injections SR tablets Tablets Codeine subtotal Injections Tablets Fentanyl, transdermal patch Meperidine subtotal Injections Tablets Buprenorphine, sublingual Total

81 58 21 33 92 19 81 15 58 56 3 19

1054 (39.7) 397 (15.0) 330 (12.4) 327 (12.3) 457 (17.2) 59 (2.2) 398 (15.0) 249 (9.4) 784 (29.5) 745 (28.1) 39 (1.5) 110 (4.1) 2654

787,260 (75.3) 12,450 (1.2) 594,750 (56.9) 180,060 (17.2) 51,882 (5.0) 353 (0.03) 51,930 (4.9) 153,750 (14.7) 25,905 (2.5) 18,560 (1.8) 7,345 (0.7) 26,328 (2.5) 1045,125

(50.9) (36.5) (13.2) (20.8) (57.9) (11.9) (50.9) (9.4) (36.5) (35.2) (1.9) (12.0)

OMEQ per opioid prescription 31.4 ± 6.2 1802 ± 1122 550.6 ± 499.2 6.0 ± 1.9 129.5 ± 115.7 617.5 ± 372.2 24.9 ± 22.6 188.3 ± 52.5 239.3 ± 224.3

Total OTD 9706 (45.4) 399 (1.9) 4794 (22.4) 4513 (21.1) 4928 (23.0) 63 (0.3) 4865 (22.7) 4206 (19.7) 1281 (6.0) 796 (3.7) 485 (2.3) 1279 (6.0) 21,400

OTD per opioid prescription 1.0 ± 0.1 14.5 ± 5.0 13.8 ± 6.8 1.1 ± 0.3 12.2 ± 8.3 16.9 ± 7.0 1.1 ± 0.5 12.4 ± 3.8 11.6 ± 5.3

Data are presented as n (%) or mean ± SD. CNCP ¼ chronic noncancer pain; COT ¼ chronic opioid therapy; NSAID ¼ nonsalicylate anti-inflammatory drug; OMEQ ¼ oral morphine equivalent dose; OTD ¼ opioid therapeutic day. a Percentages of patients treated with five different opioids were calculated by dividing the number by the count of COT-requiring CNCP patients. Some patients received more than two prescription forms of opioids or different opioids during the 2-year period.

Please cite this article in press as: Chang S-C, et al., Pharmacoepidemiology of chronic noncancer pain patients requiring chronic opioid therapy: A nationwide population-based study, Acta Anaesthesiologica Taiwanica (2015), http://dx.doi.org/10.1016/j.aat.2015.04.002

Pharmacoepidemiology of chronic noncancer pain patients

5

Table 4 Causes of visits by COT-requiring CNCP patients for their analgesic prescriptions.a,b Diseases

CNCP patients (n ¼ 159)

Myalgia and myositis, unspecified (ICD-9 729.1) Lumbago (ICD-9 724.2) Abdominal pain, unspecified site (ICD-9 789.00) Neuralgia, neuritis, and radiculitis, unspecified (ICD-9 729.2) Headache (ICD-9 784.0) Backache, unspecified (ICD-9 734.5) Sciatica (ICD-9 724.3) Lumbosacral spondylosis without myelopathy (ICD-9 721.3) Chronic pancreatitis (ICD-9 577.1) Osteoarthrosis, unspecified (ICD-9 715.90)

45 41 41 37

(28.3) (25.8) (25.8) (23.3)

37 35 24 22

(23.3) (22.0) (15.1) (13.8)

17 (10.7) 15 (9.4)

Data are presented as n (%). CNCP ¼ chronic noncancer pain; COT ¼ chronic opioid therapy. a The 159 COT-requiring CNCP patients had diverse and variable diagnoses in different departments during the 2-year period. b Essential hypertension (ICD-9 401.9), dizziness and giddiness (ICD-9 780.4), type II diabetes mellitus (ICD-9 250.00), insomnia (ICD-9 780.52), peptic ulcer (ICD9 533.90), and chronic renal failure (ICD-9 585) have not been listed in this table, because they were determined to be comorbidities of CNCP patients instead of pain causes.

performance and worse economic households, justifying the need of physical/occupational therapy when appropriate in combination with drug therapy.29 As evident from their analgesic-seeking behaviors, 46.5% of CNCP patients have visited EDs for their pain issues and ED interpreted 27.8% of opioid-obtaining outpatient visits. Although ED was a major place for them to get their pain managed, ED could provide only a few therapeutic days, implying that ED was a less-thanoptimal choice to treat CNCP patients on a chronic basis.30 This phenomenon of ED overutilization popularized among COTrequiring CNCP patients was comparable with the context disclosed in other researches.30,31 Nevertheless, in our study, we found that these patients obtained opioid prescriptions only in 13% of their analgesic-obtaining ambulatory visits and usually gained prescribed opioids from 1.8 ± 1.2 different departments (mean ± standard deviation, data not shown). Particularly contrary to the common speculation that these patients came to ED because they lacked a primary care physician, COT-requiring CNCP patients were also treated under other subspecialist's care in the meantime, suggesting inadequate pain relief.32 Pain clinic was the major department to satisfy their pharmacological need to alleviate chronic pain, which made for about one-quarter of opioidobtaining ambulatory visits and accounted for a significant portion of opioid consumption (74.2% of OMEQ) and therapeutic duration (44.9% of OTD) of all opioids. Yet only 20.8% of CNCP patents visited pain clinics to obtain opioids for pain control, although pain subspecialists were supposed to be more efficient experts in pain management or have more positive attitudes toward CNCP patients.4 Thus, more efforts are needed to place COTrequiring CNCP patients in the appropriate place to manage their pain problems on a chronic basis. For COT-requiring CNCP patients, morphine was most frequently prescribed, followed by meperidine, in opioidobtaining outpatient visits. Morphine also accounted for the majority of opioids consumed in OMEQ and also for the most OTDs among all opioids, followed by codeine and transdermal fentanyl patch. Thus, morphine was the most important opioid used for chronic pain management in these patients. Furthermore, we found that injection formulas of morphine, codeine, and meperidine were given to some CNCP patients even on a chronic basis. Although meperidine is not recommended for chronic pain

management, meperidine still accounted for 29.5% of opioid prescriptions among these 159 patients and meperidine injections were ordered in 95.0% of all meperidine prescriptions. Moreover, COT-requiring CNCP patients could get only a small number of meperidine therapeutic days (1.6 ± 2.7 days) in a single prescription. This accorded with the belief that meperidine is prescribed continuously to CNCP patients by some physicians in spite of the long list of potential side effects of chronic meperidine use and the availability of other effective opioids.33 The common use of meperidine in CNCP patients conformed with the previous findings that meperidine was prescribed improperly and increasingly to nonoperation patients without cancer diagnoses in the ambulatory/emergency settings in Taiwan.20 Conclusively, further investigation of the appropriateness of opioid use in COTrequiring CNCP patients is warranted. The leading diseases that made COT-requiring CNCP patients ask for opioids in ambulatory visits were unspecified myalgia and myositis (ICD-9 729.1), followed by lumbago (ICD-9 724.2); abdominal pain of unspecified site (ICD-9 789.00); neuralgia, neuritis, and radiculitis, unspecified (ICD-9 729.2); and headache (ICD-9 784.0). Our major concerns about the true etiology of CNCP were the fact that multiple diagnostic codes were usually given for single outpatient visit, and overlapping entity or ambiguities between unspecified myalgia, myositis, lumbago, unspecified neuralgia, neuritis, and radiculitis probably existed. Because unspecified myalgia and myositis (ICD-9 729.1), lumbago (ICD-9 724.2), unspecified backache (ICD-9 734.5), and lumbosacral spondylosis without myelopathy (ICD-9 721.3) took a great part in the visit causes, we could conclude that the diseases of the musculoskeletal system and connective tissue remained the main causes of COT-requiring CNCP. Nevertheless, this conclusion coincided with previous CNCP studies that lower back pain was the major syndrome of CNCP.27,34,35 Abdominal pain of an unspecified site (ICD-9 789.00) was the third common diagnosis for CNCP patients, yet chronic pancreatitis (ICD-9 577.1) coexisted in 36.6% cases (data not shown) of abdominal pain of unspecified site. The aforementioned findings that COT-requiring CNCP patients had diverse diagnoses in ambulatory services probably implied the heterogeneity of the underlying conditions of CNCP, or multiple pain sites involved in pain syndrome.36 5. Conclusion Most of COT-requiring CNCP patients were low-income thresholds associated with unfavorable socioeconomic status, and some of them frequented EDs for short-term pain relief, making it necessary to allocate these patients to appropriate departments that could provide efficient analgesic management on a chronic basis, to enhance their well-being as well as medical utilization. Our findings also suggest that further investigation of the appropriateness and effectiveness of opioid use in CNCP patients is necessary to improve their pain control. Acknowledgments This study was sponsored by E-DA Hospital, under its Institutional Research Project Program (institution project number: EDAHP-101032). This study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health, and managed by National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of the Bureau of National Health Insurance, Department of Health, or National Health Research Institutes.

Please cite this article in press as: Chang S-C, et al., Pharmacoepidemiology of chronic noncancer pain patients requiring chronic opioid therapy: A nationwide population-based study, Acta Anaesthesiologica Taiwanica (2015), http://dx.doi.org/10.1016/j.aat.2015.04.002

6

S.-C. Chang et al.

References 1. Rashiq S, Dick BD. Factors associated with chronic noncancer pain in the Canadian population. Pain Res Manag 2009;14:454e60. 2. Lin TC, Hsu CH, Lu CC, Tsai YC, Ho ST. Chronic opioid therapy in patients with chronic noncancer pain in Taiwan. J Anesth 2010;24:882e7. 3. Warner EA. Opioids for the treatment of chronic noncancer pain. Am J Med 2012;125:1155e61. 4. Evans L, Whitham JA, Trotter DR, Filtz KR. An evaluation of family medicine residents' attitudes before and after a PCMH innovation for patients with chronic pain. Fam Med 2011;43:702e11. 5. Bottger E, Diehlmann K. [Selected interventional methods for the treatment of chronic pain: part 2: regional anesthetic techniques close to the spinal cord and neuromodulative methods]. Der Anaesthesist 2011;60:571e90 [In German, English abstract]. 6. Bensmail D, Ecoffey C, Ventura M, Albert T, SOFMER French Society for Physical Medicine and Rehabilitation. Chronic neuropathic pain in patients with spinal cord injury. What is the efficacy of regional interventions? Sympathetic blocks, nerve blocks and intrathecal drugs. Ann Phys Rehabil Med 2009;52:142e8. 7. Coluzzi F, Pappagallo M, National Initiative on Pain Control. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol 2005;71:425e33. 8. Auret K, Schug SA. Underutilisation of opioids in elderly patients with chronic pain: approaches to correcting the problem. Drugs Aging 2005;22:64154. 9. Brown RL, Fleming MF, Patterson JJ. Chronic opioid analgesic therapy for chronic low back pain. J Am Board Fam Pract 1996;9:191e204. 10. Cheatle MD, O'Brien CP. Opioid therapy in patients with chronic noncancer pain: diagnostic and clinical challenges. Adv Psychosom Med 2011;30: 61e91. 11. Reid KJ, Harker J, Bala MM, Truyers C, Kellen E, Bekkering GE, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin 2011;27:449e62. 12. Harker J, Reid KJ, Bekkering GE, Kellen E, Bala MM, Riemsma R, et al. Epidemiology of chronic pain in Denmark and Sweden. Pain Res Treat 2012;2012: 371248. 13. Moulin DE, Clark AJ, Speechley M, Morley-Forster PK. Chronic pain in Canadadprevalence, treatment, impact and the role of opioid analgesia. Pain Res Manag 2002;7:179e84. 14. Yu HY, Tang FI, Kuo BI, Yu S. Prevalence, interference, and risk factors for chronic pain among Taiwanese community older people. Pain Manag Nurs 2006;7:2e11. 15. Freburger JK, Holmes GM, Agans RP, Jackman AM, Darter JD, Wallace AS, et al. The rising prevalence of chronic low back pain. Arch Intern Med 2009;163: 251e8. 16. Smith M, Davis MA, Stano M, Whedon JM. Aging baby boomers and the rising cost of chronic back pain: secular trend analysis of longitudinal Medical Expenditures Panel Survey data for years 2000 to 2007. J Manipulative Physiol Ther 2013;36:2e11. 17. Leverence RR, Williams RL, Potter M, Fernald D, Unverzagt M, Pace W, et al. Chronic non-cancer pain: a siren for primary careda report from the PRImary Care MultiEthnic Network (PRIME Net). J Am Board Fam Med 2011;24: 551e61.

18. Cicero TJ, Wong G, Tian Y, Lynskey M, Todorov A, Isenberg K. Co-morbidity and utilization of medical services by pain patients receiving opioid medications: data from an insurance claims database. Pain 2009;144:20e7. 19. Eriksen J, Jensen MK, Sjogren P, Ekholm O, Rasmussen NK. Epidemiology of chronic non-malignant pain in Denmark. Pain 2003;106:221e8. 20. Pan HH, Li CY, Lin TC, Wang JO, Ho ST, Wang KY. Trends and characteristics of pethidine use in Taiwan: a six-year-long survey. Clinics 2012;67:749e55. 21. Liu C-Y, Hung Y-T, Chuang Y-L, Chen Y-J, Weng W-S, Liu J-S, et al. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag 2006;4:1e22. 22. Svendsen K, Borchgrevink P, Fredheim O, Hamunen K, Mellbye A, Dale O. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med 2011;25:725e32. 23. Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A. National Opioid Use Guideline G. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations. Can Fam Phys 2011;57:1269e76. e419e28. 24. Shyr M-H. Opioid therapy in chronic nonmalignant pain. Tzu Chi Nurs J 2003;2: 31e7. 25. Lee W, Yan YY, Jensen MP, Shun SC, Lin YK, Tsai TP, et al. Predictors and patterns of chronic pain three months after cardiac surgery in Taiwan. Pain Med 2010;11:1849e58. 26. Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006;125: 172e9. 27. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain 2010;11:1230e9. 28. Hanley O, Miner J, Rockswold E, Biros M. The relationship between chronic illness, chronic pain, and socioeconomic factors in the ED. Am J Emerg Med 2011;29:286e92. 29. Sanders SH, Harden RN, Vicente PJ. Evidence-based clinical practice guidelines for interdisciplinary rehabilitation of chronic nonmalignant pain syndrome patients. Pain Pract 2005;5:303e15. 30. Woodhouse J, Peterson M, Campbell C, Gathercoal K. The efficacy of a brief behavioral health intervention for managing high utilization of ED services by chronic pain patients. J Emerg Nurs 2010;36:399e403. 31. Todd KH, Cowan P, Kelly N, Homel P. Chronic or recurrent pain in the emergency department: national telephone survey of patient experience. West J Emerg Med 2010;11:408e15. 32. Wilsey BL, Fishman SM, Ogden C, Tsodikov A, Bertakis KD. Chronic pain management in the emergency department: a survey of attitudes and beliefs. Pain Med 2008;9:1073e80. 33. Clubb B, Loveday W, Ballantyne S. Meperidine: a continuing problem. Subst Abuse 2013;7:127e9. 34. Schopflocher D, Taenzer P, Jovey R. The prevalence of chronic pain in Canada. Pain Res Manag 2011;16:445e50. 35. Portenoy RK, Bennett DS, Rauck R, Simon S, Taylor D, Brennan M, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 2006;7:583e91. 36. Wong WS, Fielding R. Prevalence and characteristics of chronic pain in the general population of Hong Kong. Journal Pain 2011;12:236e45.

Please cite this article in press as: Chang S-C, et al., Pharmacoepidemiology of chronic noncancer pain patients requiring chronic opioid therapy: A nationwide population-based study, Acta Anaesthesiologica Taiwanica (2015), http://dx.doi.org/10.1016/j.aat.2015.04.002